Loading issue research
Guarantee end-of-life care, agency, disability support, clinician conscience, and anti-coercion safeguards while leaving medical-aid-in-dying authorization to democratic conscience.
Verification Status
AI-researched, unverifiedLast Reviewed
Jul 11, 2026
Cited Sources
0
Implementation, sequencing, safeguards, tradeoffs, and the practical path from principle to policy.
The Innovation Party guarantees a common end-of-life rights and care floor while protecting a conscience space around whether a state authorizes medical aid in dying. A party member may support a narrow permitting law for a decisionally capable terminal adult or may conclude that medicine and government must not intentionally facilitate death. National party discipline does not decide that final moral question. It does require both sides to preserve treatment refusal, aggressive symptom relief, disability support, clinician conscience, accurate information, privacy, lawful travel, and protection from institutional steering.
This narrow policy excludes euthanasia, requests by a surrogate, advance authorization after capacity is lost, minors, and eligibility based only on disability, age, dependence, poverty, chronic illness, dementia, or psychiatric illness. It does not weaken the existing right to refuse treatment, receive proportionate pain relief, use palliative sedation for refractory symptoms, or choose hospice. Those practices have different acts, intentions, and legal rules and should remain available whether a state authorizes medical aid in dying or not.
The governing sentence is simple: Choice at the end of life must never become pressure to end a life. The first half requires legal agency. The second requires care, disability equality, anti-steering rules, clinician conscience, independent review, and public evidence. Either half without the other fails.
People of good faith disagree about whether intentionally hastening death can ever be part of healing. The American Medical Association opposes physician-assisted suicide while recognizing the moral seriousness of both views and protecting the conscience of physicians who legally participate. The American Academy of Hospice and Palliative Medicine takes a position of studied neutrality, distinguishes the practice from palliative care, and insists that no clinician be compelled. Disability organizations have warned that a society which undervalues disabled lives cannot assume every formal request is free of that pressure.
The party asks what government may compel and what a dependent person needs for consent to be meaningful, while recognizing the good-faith moral disagreement.
A capable adult ordinarily controls medical treatment, including refusal of treatment that could prolong life. Medical aid in dying adds a clinician's prescription and an intentional life-ending act, so government may impose a much narrower eligibility rule and stronger process than ordinary refusal. A categorical ban can force a capable terminal adult through a decline the person rejects. A permitting law can enlist medicine in an intentional death and expose dependent people to errors that cannot be repaired. Preserving life and respecting agency are both legitimate public purposes. The party cannot make either concern disappear by requiring one moral conclusion from every member.
Formal autonomy is not enough. A patient who lacks pain control, home assistance, accessible communication, protection from abuse, or relief for a desperate caregiver does not face the same choice as a patient who has those supports. The answer is not to make support an exhaustion requirement that forces unwanted treatment. It is to make the alternatives available, independently verified, and impossible for an insurer or institution to withhold as leverage.
In Washington v. Glucksberg the Supreme Court held that a right to assistance in committing suicide is not a fundamental liberty interest protected by the Due Process Clause. In Vacco v. Quill it upheld the legal distinction between refusing life-sustaining treatment and assisted suicide against an equal-protection challenge. Those decisions allow states to prohibit the practice. They do not require prohibition or invalidate state authorization.
Gonzales v. Oregon later held that the Controlled Substances Act did not give the Attorney General the claimed power to make Oregon-compliant prescriptions a federal crime. The case is about delegated statutory authority, not a constitutional right. Congress could change federal law within its powers, and a future executive could test a different theory. A clear federal safe harbor is therefore more durable than relying on one rejected interpretive rule.
The Assisted Suicide Funding Restriction Act of 1997 bars federal health funds from paying for items or services furnished to cause or assist death. It expressly leaves withdrawal of treatment and symptom relief outside that prohibition. The result is a two-level system: state law can authorize medical aid in dying while veterans, federal employees, and patients whose care depends on federal programs face separate barriers.
The current Constitution gives states broad authority over medical practice and criminal law, and Glucksberg forecloses the claim that the Fourteenth Amendment already supplies a right to assistance. The authorization question therefore remains with state democratic conscience. Congress should protect the common care, information, travel, privacy, disability, conscience, and anti-steering floor within its powers and clarify federal rules for states that authorize. It should not compel every state to legalize or turn public payment for the life-ending act into a national party requirement.
A constitutional amendment is strategically unwise. It would freeze one answer to a detailed and contested moral question into constitutional text, is not needed for states or Congress to use their existing powers, and has no credible Article V path. The durable route is a national care-and-rights floor, state deliberation, and conditional safeguards for any state that permits the practice.
Any state that authorizes medical aid in dying should treat the following as a minimum, not a template for expanding the practice.
Eligibility should require all of the following:
The terminal disease must carry eligibility. Disability, dependence in activities of daily living, age, poverty, homelessness, family burden, chronic illness, dementia, or a psychiatric diagnosis cannot substitute for it. A person with ALS may qualify because ALS is expected to cause death within six months, not because paralysis makes that life less valuable. A person with a disability and terminal cancer is assessed under the same cancer standard as anyone else. A person with dementia may qualify while still capable because of a separate terminal disease, but an advance directive cannot authorize the act after contemporaneous capacity is lost.
Psychiatric illness alone should not establish eligibility. The difficulty is not a claim that people with psychiatric illness lack agency. It is that irremediability, terminal timing, and the boundary between a sustained autonomous wish and treatable suicidal crisis are less reliably established under the proposed six-month medical rule. The party should keep that boundary unless evidence and assessment methods become strong enough to support a distinct public debate.
Six months is already used by Medicare hospice and state aid-in-dying laws. It creates a familiar, administrable boundary tied to terminal disease. It is not a precise prediction. Systematic reviews find wide variation in clinicians' survival estimates, and Oregon reported that 24 of the 400 people recorded as dying under its law in 2025 outlived the six-month prognosis after receiving a prescription.
The law should respond to uncertainty without demanding impossible certainty:
A person should not lose eligibility merely because a treatment exists in theory. The clinician must explain feasible treatments and their burdens. The patient may refuse them. Eligibility follows the disease's expected course under the patient's informed treatment choices, just as hospice eligibility can reflect the illness running its normal course.
Two clinicians saying "capable" is not enough unless the law defines how they reached the conclusion. Every requester should receive a structured capacity and distress screen using a protocol designed for end-of-life decisions. Current research has not identified an existing instrument that transfers perfectly to assisted-dying requests, so the protocol must be validated, published, and revised rather than treated as a finished scientific answer.
At least one interview must occur without a family member, caregiver, heir, facility representative, insurer, or prescribing advocate present. A qualified interpreter or communication assistant may participate but must be independent where practical. The interviewer should ask about abuse, threats, housing, debt, caregiving strain, benefit loss, fear of institutionalization, untreated symptoms, depression, grief, demoralization, and who first raised the option.
A positive or uncertain screen triggers an evaluation by a psychiatrist, psychologist, neuropsychologist, or other professional qualified for the condition at issue. Approval pauses until the evaluator determines that impaired judgment is absent or has been sufficiently addressed. A blanket psychiatric examination for every patient would consume scarce specialists and make access depend on geography. A structured universal screen plus mandatory specialist escalation is more proportionate.
The written request should have two witnesses. Neither should be entitled to the patient's estate, financially responsible for the patient's care, employed by a facility providing the patient's residential care, or part of the prescribing team. The independent navigator should document who first mentioned medical aid in dying and any material conflict without treating family involvement itself as suspicious.
Information about an unavailable service is not an alternative. Before approval, an independent navigator should create a choice-set record showing what the patient requested, what was offered, what was authorized, what remains unavailable, and what the patient declined. The record must cover:
Public and private insurers should make expedited coverage decisions for services identified in this review. A denial must receive rapid independent appeal before the prescription is dispensed unless delay would likely cause death or loss of capacity. In that circumstance the aid-in-dying review may continue, but the denial and urgency become an automatic oversight event.
An insurer, utilization contractor, facility, or public program may not introduce medical aid in dying in the same communication that denies, narrows, or delays requested life-sustaining, palliative, disability, home, or mental-health care. It may answer a patient-initiated question with neutral information. It may not present death as the cheaper covered alternative. Staff compensation, quality metrics, and benefit design may not reward steering toward the option.
This rule addresses the strongest disability critique at its source. It does not require a patient to prove that life is unbearable or perform gratitude for services. It requires the institutions controlling the choice set to show they did not manufacture the request through deprivation.
The default reflection period should be seven days between the first request and the final request, with at least forty-eight hours between the witnessed written request and dispensing. Seven days provides a second moment for reflection while recognizing that a fifteen-day rule can consume a large share of a person's remaining life.
Two clinicians may shorten the period when they independently document that the patient is likely to die or lose decision-making capacity before it expires. Shortening never waives the second prognosis, capacity assessment, private interview, care-and-support review, written request, or final contemporaneous consent. Administrative delay by an insurer, facility, or provider cannot be counted as the patient's reflection period while also preventing the required reviews from occurring.
The patient may rescind at any time and in any manner. Silence, hesitation, resistance, loss of communication without a reliable accessible method, or loss of capacity stops the process. Possessing the medication creates no duty to use it. The oversight system should report how many prescriptions are never used without treating nonuse as failure.
The patient-control boundary separates this position from euthanasia. A clinician may assess, prescribe, dispense, prepare permitted equipment, explain, and remain present. The patient must perform the final voluntary action that begins delivery. No other person may decide that the moment has arrived or activate the medication.
A hand-strength test is a poor proxy for agency. The law should permit certified adaptive equipment and non-substantive physical assistance that positions or prepares a device, so long as the capable patient alone initiates delivery through a reliable voluntary action. That could include a switch or another accessible control after safety validation. It may not include another person pushing a plunger, pouring medication into the patient's mouth, activating a device, interpreting an ambiguous movement, or continuing after the patient signals resistance.
This standard will not serve every otherwise eligible person. Some people with advanced neuromuscular disease may retain capacity while losing every reliable voluntary movement. Allowing a clinician to administer medication would answer that access problem by crossing the position's central boundary. The party should invest in validated accessible delivery methods and accept that the final-act requirement remains a hard limit unless a future public review justifies a different category.
No individual clinician, pharmacist, nurse, interpreter, social worker, or other worker should be compelled to prescribe, dispense, prepare, attend, or participate. Employment rules should permit confidential advance notice and prompt recusal without requiring a theological defense. A worker may not abandon a patient in an emergency, falsify information, obstruct records, or harass a patient or colleague.
The institution has a different duty because it controls the route. In a state that authorizes the practice, every health system and insurer should provide neutral information and a timely connection to a willing independent team. A private institution with a stated moral identity may prohibit the life-ending act on its premises when a practical transfer or outside route exists and the patient can move without material medical risk. It must still permit conversations, records transfer, palliative care, emergency stabilization, and discharge planning. A sole regional hospital, public facility, or exclusive public contractor carries a higher continuity obligation and cannot make a lawful option disappear by owning every door.
Clinician conscience also protects participation. A public authority or private employer should not punish a clinician merely for lawful practice outside a nonparticipating institution's premises and employment role. Professional standards, reporting, competence, and patient-safety rules still apply.
The dispensing pharmacy should use tamper-evident packaging, verify the authorized recipient, provide safe-storage instructions, and offer a lockbox. The patient should designate a person or service to return unused medication after death, rescission, or expiration. Pharmacies and take-back programs need a legally clear method to receive and destroy the medication.
Every patient should be offered attendance by a trained willing clinician or end-of-life professional, but attendance should not be mandatory. Mandating it would sacrifice privacy and create an access bottleneck. The patient and chosen family should receive a plain-language plan for expected effects, possible complications, when to call for help, what emergency responders will do, and how the patient's treatment preferences will be communicated. The presence or absence of a professional and the outcome should be reported.
The state should require prompt reporting of regurgitation, prolonged time to unconsciousness or death, regained consciousness, emergency intervention, medication error, diversion, suspected coercion, and any death inconsistent with the expected process. Reporting a complication should trigger clinical review and correction, not automatic criminal suspicion.
Families and caregivers should receive voluntary grief support whether the patient uses the medication, dies from the disease, or rescinds. A patient's privacy controls who is involved during life. After death, oversight can examine records under confidentiality without turning the family's grief into a public case file.
Oregon's health authority says its law creates no special oversight or regulation beyond ordinary medical care and that it does not investigate whether diagnosis, prognosis, eligibility, or treatment options were correctly determined. Its annual report is valuable, but a reporting system based mainly on participating clinicians cannot establish what it is not designed to observe.
Each authorizing state should establish an independent End-of-Life Choice Review Office with clinical, disability, ethics, data, and investigative capacity. It should:
The office should not preapprove every request. Mandatory case-by-case bureaucracy would add delay, invite political control, and make a right depend on administrative staffing. Prospective rules, a rapid consultation service, complete reporting, risk-based audits, and complaint- triggered investigation create answerable power without placing a political board at the bedside.
Public reports should include requests, approvals, denials by reason, prescriptions, ingestion, nonuse, disease, prognosis range, time to death, outliving estimates, capacity escalations, services requested and unavailable, hospice and palliative participation, complications, unused medication recovery, professional attendance, geography, race, disability status, insurance, language, and provider concentration. Small cells must be suppressed and public microdata must not make a person identifiable.
Congress should enact an End-of-Life Care and Conscience Act that:
If a state authorizes the practice, it should enact the eligibility and medical-practice framework above and may adopt stronger safeguards consistent with the same patient and disability rights. A state may instead prohibit intentional assistance under current constitutional law. It must still preserve the common end-of-life floor and cannot obstruct neutral discussion, ordinary symptom care, or lawful travel.
The national compact should be reviewed after five years by an independent panel including patients, palliative and hospice clinicians, disability advocates supporting and opposing the practice, participating and objecting clinicians, capacity experts, elder-abuse specialists, pharmacists, rural providers, caregivers, insurers, data scientists, constitutional counsel, and state regulators. The review should recommend continuation, correction, expansion, or contraction from the evidence. It should not allow the program to expire automatically and strand people while Congress fails to act.
Innovation here makes a morally serious choice safer, more accessible, more observable, and less dependent on physical strength, wealth, geography, or institutional luck.
The practical innovation agenda includes calibrated prognosis tools that disclose uncertainty; validated capacity protocols; privacy-preserving outcome data; accessible communication; adaptive patient-controlled delivery; interoperable consent and revocation records; rapid coverage appeals; anomaly detection for provider or insurer patterns; tele-palliative support for rural patients; and audit systems that can learn without exposing families. Every tool must assist a human judgment, preserve an appeal, and publish its limits.
The highest-value innovation may be organizational. A single independent navigator who can see the patient's clinical, service, financial, family, and accessibility barriers can detect pressure that fragmented specialists miss. A choice-set record converts "alternatives were discussed" into a verifiable account of whether the alternatives existed. A complication registry turns private failures into public learning. These are technologies of answerable care as much as software products.
A complete ban. A ban protects against wrongful eligibility and affirms a healing norm. It also forces every capable terminal adult to accept the state's answer and may push some people toward violent, lonely, or medically unmanaged methods. The party protects a conscience vote on the ban while requiring its proponents to own that cost and preserve the common care floor.
Autonomy without a terminal boundary. A broad rule based on intolerable suffering would reduce line-drawing and include chronic or psychiatric suffering. It would also make irremediability, social deprivation, disability bias, and fluctuating desire carry far more weight. The conditional authorization model retains the six-month disease boundary.
Mandatory judicial approval. A court could add independence. It would also turn a time-limited medical decision into litigation, reward people with counsel, and invite judges to substitute moral belief for clinical standards. Independent clinical review and audit are better fitted to the task.
Mandatory psychiatric examination for everyone. Universal specialist review sounds safer but would create long delays and severe rural inequity without evidence that every case needs it. Universal structured screening with mandatory escalation focuses scarce expertise where uncertainty exists.
Clinician administration. It would include patients who cannot self-initiate. It would also transfer the final act from patient to professional and create a different moral and regulatory category. The conditional authorization model permits validated adaptive control but not euthanasia.
No waiting period. Immediate access avoids procedural cruelty. It removes a useful second moment in a decision that cannot be reversed. A short, waivable period with nonwaivable core safeguards better fits both risks.
Institutional absolute conscience. Full institutional refusal protects associational identity but can erase accurate information and ordinary end-of-life care where systems own the only hospital, network, or insurer. The party protects refusal to perform the contested act while retaining continuity duties for information, records, emergencies, palliative care, and safe transfer.
Turn frustration into useful pressure.
If this position misses evidence or a lived consequence, challenge it. If it holds up, help test it locally and connect it to the issues around it.